1. Stein DJ. Obsessive-compulsive disorder. Lancet 2002;360:397-405.
2. Jenike MA. Obsessive-compulsive disorder. N Engl J Med 2004;350:259-265.
3. Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive disorder. Expert Opin Emerg Drugs 2014;19:67-77.
5. Khalsa SS, Schiffman JE, Bystritsky A. Treatment-resistant OCD: options beyond first-line medications. Curr Psychiatry 2011;10:44-52.
8. Albert U, Aguglia A, Bramante S, Bogetto F, Maina G. Treatment-resistant obsessive-compulsive disorder (OCD): current knowledge and open questions. Clin Neuropsychiatry 2013;10:19-30.
9. Alonso P, Menchon JM, Pifarre J, Mataix-Cols D, Torres L, Salgado P, et al. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 2001;62:535-540.
10. Ackerman DL, Greenland S, Bystritsky A. Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 1999;19:459-465.
11. Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:488-492.
14. Maltby N, Tolin DF. Overview of treatments for obsessive-compulsive disorder and spectrum conditions: conceptualization, theory, and practice. Br Treat Cris Interv 2003;3:127-144.
15. Marazziti D, Picchetti M, Baroni S, Ceresoli D, Consoli G, Catena Dell’Osso M. Current pharmacological and non pharmacological treatments for obsessive-compulsive disorder. J Psychopathol 2012;18:5-18.
16. Koran LM, Hollander E, Nestadt G, Simpson HB. Practice Guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007;64(7 suppl):5-53.
17. Kishore VR, Samar R, Janardhan Reddy YC, Chandrasekhar CR, Thennarasu K. Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. Eur Psychiatry 2004;19:202-208.
18. Shetti CN, Reddy YCJ, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, et al. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry 2005;66:1517-1523.
19. Hantouche EG, Bouhassira M, Lancrenon S. Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study. Encephale 2000;26:73-83.
20. Catapano F, Sperandeo R, Perris F, Lanzaro M, Maj M. Insight and resistance in patients with obsessive-compulsive disorder. Psychopathology 2001;34:62-68.
21. Matsunaga H, Kiriike N, Matsui T, Oya K, Iwasaki Y, Koshimune K, et al. Obsessive-compulsive disorder with poor insight. Compr Psychiatry 2002;43:150-157.
22. Ng R, Fish S, Granholm E. Insight and theory of mind in schizophrenia. Psychiatry Res 2015;225:169-174.
23. Frith U, Happé F, Granholm E. Autism: beyond “theory of mind.”. Cognition 1994;50:115-132.
24. Frith C, Frith U. Theory of mind. Curr Biol 2005;15:R644-R645.
25. Ntouros E, Bozikas VP, Andreou C, Kourbetis D, Lavrentiadis G, Garyfallos G. Emotional perception and theory of mind in first episode psychosis: the role of obsessive-compulsive symptomatology. Psychiatry Res 2014;220:112-117.
26. Darvishi N, Alilou MM, Bakhshipour A, Farnam A, Bahramkhani M. Theory of mind in obsessive-compulsive disorder patients versus normal individuals. Adv Cogn Sci 2013;15:77-89.
28. Lysaker PH, Carcione A, Dimaggio G, Johannesen JK, Nicolò G, Procacci M, et al. Metacognition amidst narratives of self and illness in schizophrenia: Associations with neurocognition, symptoms, insight and quality of life. Acta Psychiatr Scand 2005;112:64-71.
29. Fonagy P, Gergely G, Jurist EL, Target M. Affect Regulation, Mentalization and the Development of the Self. New York: Karnac Books; 2004.
30. Bateman AW, Fonagy P. Handbook of Mentalizing in Mental Health Practice. Arlington: American Psychiatric Pub; 2012.
31. Sayin A, Oral N, Utku C, Baysak E, Candansayar S. Theory of mind in obsessive-compulsive disorder: comparison with healthy controls. Eur Psychiatry 2010;25:116-122.
32. Kang JI, Namkoong K, Yoo SW, Jhung K, Kim SJ. Abnormalities of emotional awareness and perception in patients with obsessive-compulsive disorder. J Affect Disord 2012;141:286-293.
34. David AS. “To see oursels as others see us”. Aubrey Lewis’s insight. Br J Psychiatry 1999;175:210-216.
37. First MB, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington DC: American Psychiatric Press; 1997.
38. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale: I. development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
39. Tek C, Uluğ B, Rezaki BG, Tanriverdi N, Mercan S, Demir B, et al. Yale-Brown Obsessive Compulsive Scale and US National Institute of Mental Health Global Obsessive Compulsive Scale in Turkish: reliability and validity. Acta Psychiatr Scand 1995;91:410-413.
40. Hisli Şahin N. A study on the validity of Beck Depression Inventory in Turkish. Turkish J Psychol 1988;7:3-13.
41. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
43. Ulusoy M, Sahin N, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cogn Psychother An Int Q 1998;12:163-172.
44. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The “Reading the Mind in the Eyes” Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 2001;42:241-251.
45. Yildirim EA, Kaşar M, Güdük M, Ateş E, Küçükparlak I, Ozalmete EO. Investigation of the reliability of the “reading the mind in the eyes test” in a Turkish population. Turk Psikiyatr Derg 2011;22:177-186.
46. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA. The brown assessment of beliefs scale: reliability and validity. Am J Psychiatry 1998;155:102-108.
47. Özcan T, Erkan K, Şafak Y, Karadere ME, Yavuz KF, Türkçapar MH. Brown assessment of beliefs scale: a study of reliability and validity. J Cogn Psychother Res 2013;2:25-33.
48. Stewart SL, Corcoran R, Lewis SW, Drake RJ. The relationship between theory of mind and insight in psychosis: evidence for specificity. Psychosis 2010;2:34-40.
49. Quee PJ, van der Meer L, Krabbendam L, de Haan L, Cahn W, Wiersma D, et al. Insight change in psychosis: relationship with neurocognition, social cognition, clinical symptoms and phase of illness. Acta Psychiatr Scand 2014;129:126-133.
50. Catapano F, Perris F, Fabrazzo M, Cioffi V, Giacco D, De Santis V, et al. Obsessive-compulsive disorder with poor insight: a three-year prospective study. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:323-330.
51. Solyom L, DiNicola VF, Phil M, Sookman D, Luchins D. Is there an obsessive psychosis? Aetiological and prognostic factors of an atypical form of obsessive-compulsive neurosis. Can J Psychiatry 1985;30:372-380.
52. Praško J, Raszka M, Adamcova K, Grambal A, Koprivova J, Kudrnovska H, et al. Predicting the therapeutic response to cognitive behavioural therapy in patients with pharmacoresistant obsessive-compulsive disorder. Neuroendocrinol Lett 2009;30:615-623.
54. Alonso P, Menchón JM, Segalàs C, Jaurrieta N, Jiménez-Murcia S, Cardoner N, et al. Clinical implications of insight assessment in obsessive-compulsive disorder. Compr Psychiatry 2008;49:305-312.
55. Lelliott PT, Noshirvani HF, Başoğlu M, Marks IM, Monteiro WO. Obsessive-compulsive beliefs and treatment outcome. Psychol Med 1988;18:697-702.
56. Ito LM, De Araujo LA, Hemsley DR, Marks IM. Beliefs and resistance in obsessive-complulsive disorder: observations from a controlled study. J Anxiety Disord 1995;9:269-281.
57. Steketee G, Shapiro LJ. Predicting behavioral treatment outcome for agoraphobia and obsessive compulsive disorder. Clin Psychol Rev 1995;15:317-346.
58. Türksoy N, Tükel R, Ozdemir O, Karali A. Comparison of clinical characteristics in good and poor insight obsessive-compulsive disorder. J Anxiety Disord 2002;16:413-423.
59. Bellino S, Patria L, Ziero S, Bogetto F. Clinical picture of obsessive-compulsive disorder with poor insight: a regression model. Psychiatry Res 2005;136:223-231.
60. Samuels J, Yin YS, Grados MA, Willour VL, Bienvenu OJ, Greenberg BD, et al. Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD collaborative genetics study. Am J Psychiatry 2007;164:493-499.
61. Saxena S, Maidment KM, Vapnik T, Golden G, Rishwain T, Rosen RM, et al. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment. J Clin Psychiatry 2002;63:21-27.
62. Altintaş E, Taşkintuna N. Factors associated with depression in obsessive-compulsive disorder: a cross-sectional study. Noropsikiyatri Ars 2015;52:346-353.
63. Butler G, Mathews A. Cognitive processes in anxiety. Adv Behav Res Ther 1983;5:51-62.
64. Pigott TA, Seay S. Pharmacotherapy of obsessive-compulsive disorder. Int Rev Psychiatry 1997;9:133-147.
67. Elvish J, Simpson J, Ball LJ. Which clinical and demographic factors predict poor insight in individuals with obsessions and/or compulsions? J Anxiety Disord 2010;24:231-237.
70. Cherian AV, Narayanaswamy JC, Srinivasaraju R, Viswanath B, Math SB, Kandavel T, et al. Does insight have specific correlation with symptom dimensions in OCD? J Affect Disord 2012;138:352-359.
71. Kumar H. Symptom dimensions and clinical presentations in obsessive compulsive disorder. Int J Indian Psychol 2016;59:116
72. Gubb K. Psychosomatics today: a review of contemporary theory and practice. Psychoanal Rev 2013;100:103-143.
73. Drake RJ, Lewis SW. Insight and neurocognition in schizophrenia. Schizophr Res 2003;62:165-173.
74. Harrington L, Siegert RJ, McClure J. Theory of mind in schizophrenia: a critical review. Cogn Neuropsychiatry 2005;10:249-286.
75. Bateman A, Fonagy P. 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. Am J Psychiatry 2008;165:631-638.
76. Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry 2009;166:1355-1364.
77. Fett AKJ, Viechtbauer W, Dominguez M de G, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2011;35:573-588.
79. Miguel EC, Rauch SL, Jenike MA. Obsessive-compulsive disorder. Psychiatr Clin North Am 1997;20:863-883.
81. Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders. Prog Brain Res 2008;172:423-463.
82. Assogna F, Pontieri FE, Caltagirone C, Spalletta G. The recognition of facial emotion expressions in Parkinson’s disease. Eur Neuropsychopharmacol 2008;18:835-848.
83. Tas C, Brown EC, Gonzalez C, Brüne M. Experimental Usage of Oxytocin to Combat Deficits in Social Cognition in Schizophrenia. In: Lysaker PH, editor. Social Cognition and Metacognition in Schizophrenia: Psychopathology and Treatment Approaches. San Diego, CA, USA: Academic Press/Elsevier, 2014, p. 301-312.
84. Brent BK. A mentalization-based approach to the development of the therapeutic alliance in the treatment of schizophrenia. J Clin Psychol 2015;71:146-156.